Sorrento Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Sorrento Therapeutics has a total shareholder equity of $-198.0M and total debt of $142.1M, which brings its debt-to-equity ratio to -71.8%. Its total assets and total liabilities are $456.7M and $654.6M respectively.
Key information
-71.8%
Debt to equity ratio
US$142.10m
Debt
| Interest coverage ratio | n/a |
| Cash | US$80.64m |
| Equity | -US$197.96m |
| Total liabilities | US$654.65m |
| Total assets | US$456.69m |
Recent financial health updates
Recent updates
Sorrento unit Scilex pre-emptively pays off remaining notes for $39.7M
Sep 29Sorrento Sofusa drug delivery system shows promise vs subcutaneous injection in trial
Sep 15Sorrento stock rises 13% on FDA fast track status for low back pain therapy SP-103
Aug 31Sorrento achieves positive results in pivotal trial for abivertinib in NSCLC
Aug 23Sorrento's unit Scilex inks distribution deal for pain drug ZTlido with CH Trading
Aug 17Is Sorrento Therapeutics (NASDAQ:SRNE) A Risky Investment?
Jul 22
Sorrento Therapeutics: The Enigma
Jul 15Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
Jul 07Sorrento Therapeutics: Sales Are Up But EY Identifies Internal Control Issues
Mar 15Sorrento Therapeutics: Wide Oncology Pipeline, And Watch Out For COVID Updates
Oct 09Financial Position Analysis
Short Term Liabilities: SRNE.Q has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: SRNE.Q has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: SRNE.Q has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: SRNE.Q's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SRNE.Q has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SRNE.Q has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/04 00:08 |
| End of Day Share Price | 2024/01/03 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sorrento Therapeutics, Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | Aegis Capital Corporation |
| James Molloy | Alliance Global Partners |
| Difei Yang | Brean Capital |